Maria Teresa Sandri

TL;DR: These new ESMO Clinical Practice Guidelines are the result of a multidisciplinary cardio-oncology review of current evidence with the ultimate goal of providing strict criteria-based recommendations on CV risk prevention, assessment, monitoring and management during anticancer treatment.

TL;DR: These data confirm the independent prognostic effect of CTC count on progression-free survival and overall survival and also improves the prognostication of metastatic breast cancer when added to full clinicopathological predictive models, whereas serum tumour markers do not.

TL;DR: The elevation of cTnI in patients undergoing HDC for aggressive malignancies accurately predicts the development of future LVEF depression and can be considered a sensitive and reliable marker of acute minor myocardial damage with relevant clinical and prognostic implications.

TL;DR: Continuously low-dose CTX and MTX is minimally toxic and effective in heavily pretreated breast cancer patients and alternative hypotheses, other than that of direct toxicity on tumor cells, must be favored when trying to explain the anticancer effect.

TL;DR: In this population, the elevation of TnI soon after HDC accurately predicts the development of future LVEF depression and can be considered a sensitive and reliable marker of myocardial damage with relevant clinical and prognostic implications.